Compare · CATX vs MDLN
CATX vs MDLN
Side-by-side comparison of Perspective Therapeutics Inc. (CATX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CATX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $52.27B, about 153.3x CATX ($341.0M).
- Over the past year, CATX is down 30.9% and MDLN is down 2.3% - MDLN leads by 28.5 points.
- MDLN has been more active in the news (4 items in the past 4 weeks vs 3 for CATX).
- MDLN has more recent analyst coverage (25 ratings vs 11 for CATX).
PerformanceCATX+15.06%MDLN-2.33%
2025-12-17+0.00%2026-07-17
- Company
- Perspective Therapeutics Inc.
- Medline Inc.
- Price
- $2.98+0.68%
- $39.80-3.23%
- Market cap
- $341.0M
- $52.27B
- 1M return
- +1.71%
- +7.36%
- 1Y return
- -30.86%
- -2.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NASDAQ
- IPO
- 2025
- News (4w)
- 3
- 4
- Recent ratings
- 11
- 25
Latest CATX
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
- Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor
- Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
- Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Perspective Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
- Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
- SEC Form 10-Q filed by Perspective Therapeutics Inc.
- Perspective Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)